PH 2 Pemigatinib in SDH-deficient GIST

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
PH 2 Pemigatinib in SDH-deficient GIST	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm	Recruiting	Phase 2	2026-05-22		NCT07434843

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dana-Farber Cancer Institute	324
Gateway for Cancer Research	32
Incyte Corporation	153

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana Farber Cancer Institute	Boston	United States	300

Clinical trials